Ze Wang
ABSTRACT
Tumor immunotherapy has demonstrated advantages over traditional therapies, and Anti-PD-1/PD-L1immunotherapy has become a hot topic in recent years and has shown excellent efficacy. A number of anti-PD-1/PD-L1 drugs have been approved for the market. This review briefly analyzes how PD-1 and PD-L1 affect the tumor immune function of human body, and the action mechanism of anti-PD-(L)1 drug from the perspective of molecular mechanism. Furthermore, it shows the clinical effect of anti-PD-(L)1 monotherapies and combination therapies by far.
- Sharma, P. and J.P. Allison. (2015). The future of immune checkpoint therapy. Science, 348(6230), 56--61.Google Scholar
Cross Ref
- Hanahan, D. and R.A. Weinberg. (2011). Hallmarks of cancer: the next generation. Cell, 144(5), 646--74.Google ScholarCross Ref
- Seliger, B. (2019). Basis of PD1/PD-L1 Therapies. J Clin Med, 8(12).Google Scholar
- G. J. Freeman et al. (2000). J. Exp. Med, 192, 1027--1034.Google ScholarCross Ref
- Li, L., et al. (2005). Rap1-GTP is a negative regulator of Th cell function and promotes the generation of CD4+CD103+ regulatory T cells in vivo. J Immunol, 175(5), 3133--9.Google ScholarCross Ref
- Dong, H., et al. (2002). Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med, 8(8), 793--800.Google ScholarCross Ref
- Fabrizio, F.P., et al. (2018). Gene code CD274/PD-L1: from molecular basis toward cancer immunotherapy. Ther Adv Med Oncol, 10, 1758835918815598.Google ScholarCross Ref
- Zou, W., J.D. Wolchok, and L. Chen. (2016). PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations. Sci Transl Med, 8(328), 328rv4.Google Scholar
- Zak, K.M., et al. (2015). Structure of the Complex of Human Programmed Death 1, PD-1, and Its Ligand PD-L1. Structure, 23(12), 2341--2348.Google ScholarCross Ref
- Pardoll, D.M. (2012). The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer, 12(4), 252--64.Google ScholarCross Ref
- Terme, M., et al. (2011). IL-18 induces PD-1-dependent immunosuppression in cancer. Cancer Res, 71(16), 5393--9.Google ScholarCross Ref
- Fanoni, D., et al. (2011). New monoclonal antibodies against B-cell antigens: possible new strategies for diagnosis of primary cutaneous B-cell lymphomas. Immunol Lett, 134(2), 157--60.Google ScholarCross Ref
- Freeman, G.J., et al. (2000). Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med, 192(7), 1027--34.Google ScholarCross Ref
- Dong, H., et al. (2003). B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. Nat Med, 1999. 5(12), 1365--9.Google Scholar
- Selenko-Gebauer, N., et al., B7-H1 (programmed death-1 ligand) on dendritic cells is involved in the induction and maintenance of T cell anergy. J Immunol, 170(7), 3637--44.Google Scholar
- Greenwald, R.J., G.J. Freeman, and A.H. Sharpe. (2005). The B7 family revisited. Annu Rev Immunol, 23, 515--48.Google ScholarCross Ref
- Sun, C., R. Mezzadra, and T.N. (2018). Schumacher, Regulation and Function of the PD-L1 Checkpoint. Immunity, 48(3), 434--452.Google ScholarCross Ref
- Yearley, J.H., et al. (2017). PD-L2 Expression in Human Tumors: Relevance to Anti-PD-1 Therapy in Cancer. Clin Cancer Res, 23(12), 3158--3167.Google ScholarCross Ref
- Chen, D.S. and I. Mellman. (2017). Elements of cancer immunity and the cancer-immune set point. Nature, 541(7637), 321--330.Google ScholarCross Ref
- Brahmer, J.R., et al. (2010). Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol, 28(19), 3167--75.Google ScholarCross Ref
- Sznol, M. et al. (2010). Safety and antitumor activity of biweekly MDX 1106 (Anti PD 1) in patients with advanced refractory malignancies. J. Clin. Oncol, 28 (Suppl.), Abstract 2506.Google Scholar
- Ansell, S.M., et al. (2015). PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med, 372(4), 311--9.Google ScholarCross Ref
- Robert, C., et al. (2015). Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med, 372(4), 320--30.Google ScholarCross Ref
- The first domestic pd-1 antibody drug triplezumab injection was approved for the market, http://www.nmpa.gov.cn/WS04/CL2094/333924.html.Google Scholar
- Song, Y., et al. (2020). Treatment of relapsed or refractory classical Hodgkin lymphoma with the anti-PD-1, tislelizumab: results of a phase 2, single-arm, multicenter study. Leukemia, 34(2), 533--542.Google ScholarCross Ref
- Lee, H.T., S.H. Lee, and Y.S. Heo. (2019). Molecular Interactions of Antibody Drugs Targeting PD-1, PD-L1, and CTLA-4 in Immuno-Oncology. Molecules, 24(6).Google Scholar
- Ingles Garces, A.H., et al. (2019). Building on the anti-PD1/PD-L1 backbone: combination immunotherapy for cancer. Expert Opin Investig Drugs, 28(8), 695--708.Google ScholarCross Ref
- Motzer, R.J., et al. (2018). Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma. N Engl J Med, 378(14), 1277--1290.Google ScholarCross Ref
- Niyongere, S., A. Saltos, and J.E. Gray. (2018). Immunotherapy combination strategies (non-chemotherapy) in non-small cell lung cancer. J Thorac Dis, 10(Suppl 3), S433-S450.Google ScholarCross Ref
- Sahin, U., et al. (2017). Personalized RNA mutanome vaccines mobilize polyspecific therapeutic immunity against cancer. Nature, 547(7662), 222--226.Google ScholarCross Ref
- Long G V., Dummer R, Ribas A, et al. (2016). Efficacy analysis of MASTERKEY-265 phase 1b study of talimogene laherparepvec (T-VEC) and pembrolizumab (pembro) for unresectable stage IIIB-IV melanoma. J. Clin. Oncol, 34, 9568--9568.Google ScholarCross Ref
- Davies, H., et al. (2002). Mutations of the BRAF gene in human cancer. Nature, 417(6892), 949--54.Google ScholarCross Ref
- Rini, B.I., et al. (2019). Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. N Engl J Med, 380(12), 1116--1127.Google ScholarCross Ref
- Motzer, R.J., et al. (2019). Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. N Engl J Med, 380(12), 1103--1115.Google ScholarCross Ref
- Junshi biotech announces a breakthrough in the combination therapy of tririplezumab (tuoyi) and acitinib, https://www.chemdrug.com/news/232/13/64283.html.Google Scholar
- Munn, D.H., et al. (2005). GCN2 kinase in T cells mediates proliferative arrest and anergy induction in response to indoleamine 2,3-dioxygenase. Immunity, 22(5), 633--42.Google ScholarCross Ref
- Gangadhar TC, Hamid O, Smith DC, et al. (2016). Epacadostat plus pembrolizumab in patients with advanced melanoma and select solid tumors: Updated phase 1 results from ECHO-202/KEYNOTE-037. Ann. Oncol, 27(suppl_6).Google Scholar
- Lee, J.Y., et al. (2016). Structural basis of checkpoint blockade by monoclonal antibodies in cancer immunotherapy. Nat Commun, 7, 13354.Google ScholarCross Ref
- Na, Z., et al. (2017). Structural basis for blocking PD-1-mediated immune suppression by therapeutic antibody pembrolizumab. Cell Res, 27(1), 147--150.Google ScholarCross Ref
- Tan, S., et al. (2017). An unexpected N-terminal loop in PD-1 dominates binding by nivolumab. Nat Commun, 8, 14369.Google ScholarCross Ref
Index Terms
- The Recent Advances of Anti-PD-1/PD-L1 Immunotherapy
Recommendations
Discovery of small-molecule PD-1/PD-L1 antagonists through combined virtual screening and experimental validation
AbstractInhibition of the interaction between the PD-1 protein on activated lymphocytes and the PD-L1 protein on tumors represents a novel therapeutic approach for selective activation of the innate immune response against a variety of ...
Graphical AbstractDisplay Omitted
Highlights- High throughput virtual screening was used to discover novel PD-1/PD-L1 inhibitors.
Mutating PD-1 to Avoid PD-L1 From Binding Therefore Regulates NSCLC
ISAIMS '22: Proceedings of the 3rd International Symposium on Artificial Intelligence for Medicine SciencesLung cancer is one of the most common types of cancer in human clinical cases. It has been a worldwide problem for hundreds of years. Currently, there are more research done on blocking the pathway between PD-1 and PD-L1 using drugs or antibodies; ...
Comments